Literature DB >> 12360538

The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys.

Louis C Tan1, Peter H Protell, J William Langston, Daniel M Togasaki.   

Abstract

The Hyperkinetic Abnormal Movements Scale (HAMS) was developed based on extensive observation of normal and abnormal movements in squirrel monkeys. The observations of abnormal movements were performed using animals that had undergone prior lesioning with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) that subsequently developed levodopa-induced abnormal movements. Specific and easily observable changes in behavior were used to delineate the boundaries between each rating level of the scale. The full spectrum of abnormal behavior at each rating level was then characterized for the squirrel monkey. Once the scale was fully developed and finalized, reliability testing revealed strong inter-rater (r = 0.959) and intrarater reliability (r = 0.930 to 0.941). Novice raters were easily taught its use and subsequently could use the scale with strong inter-rater reliability (R = 0.9057). In further studies of levodopa-induced abnormal movements, the HAMS was demonstrated to be highly sensitive, highly specific, and valid, both internally and when compared with an objective measure of abnormal movements. Although the scale was developed in MPTP-lesioned squirrel monkeys treated with levodopa, it might provide a framework for the standardized measurement of hyperkinetic abnormal movements in other primates and other experimental conditions. Copyright 2002 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360538     DOI: 10.1002/mds.10183

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

1.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

2.  Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Danhui Zhang; Archana Mallela; David Sohn; F Ivy Carroll; Merouane Bencherif; Sharon Letchworth; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2013-07-31       Impact factor: 4.030

3.  The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.

Authors:  Heather Cox; Daniel M Togasaki; Li Chen; J William Langston; Donato A Di Monte; Maryka Quik
Journal:  Exp Neurol       Date:  2007-02-03       Impact factor: 5.330

4.  A new quantitative rating scale for dyskinesia in nonhuman primates.

Authors:  Lisa F Potts; Subramaniam Uthayathas; Alexander C M Greven; Bhagyalaxmi Dyavarshetty; Mary M Mouradian; Stella M Papa
Journal:  Behav Pharmacol       Date:  2015-02       Impact factor: 2.293

5.  Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.

Authors:  Maryka Quik; Archana Mallela; Matthew Chin; J Michael McIntosh; Xiomara A Perez; Tanuja Bordia
Journal:  Neurobiol Dis       Date:  2012-09-23       Impact factor: 5.996

6.  The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.

Authors:  Danhui Zhang; Matthew McGregor; Michael W Decker; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2014-07-17       Impact factor: 4.030

7.  ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Danhui Zhang; Tanuja Bordia; Matthew McGregor; J Michael McIntosh; Michael W Decker; Maryka Quik
Journal:  Mov Disord       Date:  2014-02-11       Impact factor: 10.338

Review 8.  Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.

Authors:  Xiomara A Perez
Journal:  Neuropsychol Rev       Date:  2015-11-09       Impact factor: 7.444

Review 9.  Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?

Authors:  G Linazasoro; N Van Blercom; L Ugedo; J A Ruiz Ortega
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.